Gyre Therapeutics (GYRE) Work In Process (2022 - 2026)
Gyre Therapeutics (GYRE) posted quarterly Work In Process of $6.0 million for Q1 2026, up 74.82% year-over-year from $3.4 million in Q1 2025, and down 4.98% quarter-over-quarter from $6.3 million in Q4 2025.
Gyre Therapeutics (GYRE) Work In Process (2022 - 2026) Analysis & Trends
Gyre Therapeutics (GYRE) has reported Work In Process for 5 consecutive years, with $6.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Work In Process rose 74.82% year-over-year to $6.0 million; the TTM figure through Mar 2026 stood at $6.0 million (up 74.82% YoY), while the FY2025 annual figure was $6.3 million, up 115.33% from the prior year.
- Work In Process slipped to $6.0 million in Q1 2026 per GYRE's latest filing, from $6.3 million in the prior quarter.
- Across five years, Work In Process topped out at $6.3 million in Q4 2025 and bottomed at $2.0 million in Q4 2023.
- Historically, Work In Process has averaged $3.8 million across 5 years, with a median of $3.5 million in 2024.
- Annual changes were most pronounced in 2023 — Work In Process sank 45.54% — and 2025, when it soared 115.33%.
- Gyre Therapeutics' Work In Process stood at $3.7 million in 2022, then tumbled by 45.54% to $2.0 million in 2023, then soared by 46.67% to $2.9 million in 2024, then jumped by 115.33% to $6.3 million in 2025, then decreased by 4.98% to $6.0 million in 2026.
- Business Quant data shows GYRE's Work In Process at $6.0 million in Q1 2026, $6.3 million in Q4 2025, and $4.4 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Gyre Therapeutics | 708.31 Mn | 685.47 Mn | 26.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 7.71 Mn |
| Mar 31, 2026 | 5.99 Mn |
| Dec 31, 2025 | 6.31 Mn |
| Sep 30, 2025 | 4.43 Mn |
| Jun 30, 2025 | 4.21 Mn |
| Mar 31, 2025 | 3.43 Mn |
| Dec 31, 2024 | 2.93 Mn |
| Sep 30, 2024 | 3.54 Mn |
| Jun 30, 2024 | 2.92 Mn |
| Mar 31, 2024 | 2.53 Mn |
| Dec 31, 2023 | 2.00 Mn |
| Dec 31, 2022 | 3.67 Mn |